Ensitrelvir
A protease inhibitor.
General information
Ensitrelvir is a clinically trialled SARS-CoV-2 3C-like protease inhibitor. It displayed efficacy against the BA.1 Omicron variant of SARS-CoV-2 in an animal model (Uraki et al., 2022).
Ensitrelvir on PubChem
Ensitrelvir on Wikipedia
Synonyms
S-217622
Marketed as
XOCOVA
CN1C=C2C=C(C(=CC2=N1)Cl)NC3=NC(=O)N(C(=O)N3CC4=CC(=C(C=C4F)F)F)CC5=NN(C=N5)C
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
3CLpro Spike variant Novel compound Protein factor Small molecule Animal model Antibody |
VeroE6/TMPRSS2 cells; Syrian hamsters; SARS-CoV-2 live virus (D614G, Omicron BA.1, and Omicron BA.1.1) | 17.75 | The drug significantly decreased viral replication (BA.1 strain) in both upper and lower respiratory tract of Syrian hamsters upon a viral challenge. |
Jun/15/2022 |
|
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
3CLpro Spike variant Protein factor Small molecule Animal model In vitro Antibody |
VeroE6/TMPRSS2 cells; Syrian hamsters (K18-hACE2 lines); K18-hACE2 C57BL/6J mice; BALB/c mice; SARS-CoV-2 live virus (D614G, Delta, Omicron BA.1, Omicron BA.1.1, and Omicron BA.2 (various isolates)) | 49.96 | The drug significantly decreased viral replication (BA.2 strain) in lungs and nasal turbinates of Syrian hamsters upon a viral challenge. |
May/16/2022 |
